Phage therapy cannot be improvised. It must become precise, personalized, and clinically controlled.
A new clinical program in Melbourne is showing how phage therapy could become a serious weapon against life-threatening, antibiotic-resistant infections.
Researchers at The Alfred and Monash University are developing VICPhage, one of Australia’s first end-to-end clinical phage therapy services.
The program is co-led by Professor Anton Peleg, Director of the Department of Infectious Diseases at The Alfred and Monash University, and Professor Jeremy Barr, from Monash University’s School of Biological Sciences and Centre to Impact AMR. The first author of the new Nature Medicine paper is Dr Fernando Gordillo-Altamirano.
The principle is simple but powerful:
Bacteriophages are viruses that infect and kill bacteria.
Unlike broad-spectrum antibiotics, phages can be highly specific. This makes them promising for difficult infections caused by multidrug-resistant bacteria, especially when patients have no remaining options.
But this new clinical case delivers a crucial message:
Phage therapy cannot be improvised. It must become precise, personalized, and clinically controlled.
In one compassionate-use case involving a young patient with cystic fibrosis and recurrent severe infection, treatment did not succeed. But this failure revealed essential lessons for the field.
The patient’s immune system already had antibodies that could react against the therapeutic phage.
The bacterial population was not uniform; some subpopulations were less sensitive to the phage.
These findings show that future phage therapy will need more than matching a virus to a bacterium in the laboratory. It will require phage susceptibility testing, screening for anti-phage antibodies, detection of bacterial heteroresistance, regulated production, hospital-based clinical protocols, and well-designed clinical trials.
This is where the field is moving:
from emergency rescue treatment to precision infectious-disease medicine.
The strategic question now is no longer only:
Can we build the clinical ecosystem needed to deploy phage therapy safely, rapidly, and effectively?
Read the complete news by Monash University, Gordillo Altamirano, F., et al. (2026). Cross-reactive anti-prophage antibodies and bacterial heteroresistance implicated in phage therapeutic failure. Nature Medicine. here
This question will be central at Targeting Phage Therapy 2026, taking place June 9–10, 2026, in Valencia, Spain.